EGFR and non-small cell lung carcinoma: This case indicated that non-small cell lung cancer patients harboring the <i>EGFR</i> E709_T710delinsD mutation could benefit from afatinib treatment, followed with almonertinib treatment, as a potential therapeutic strategy.